Pages

Tuesday, May 12, 2015

PE recurrence same with vena cava filter plus anticoagulation as anticoagulation alone

Adding an inferior vena cava filter did not reduce the risk of recurrent pulmonary embolism (PE) compared to anticoagulation alone, according to a recent study of French patients hospitalized with PE.

The open-label trial included patients who were hospitalized with acute, symptomatic PE associated with lower-limb venous thrombosis and who met at least 1 criterion for severity between 2006 and 2012. The patients were randomized to retrievable inferior vena cava filter implantation plus anticoagulation (n=200) or anticoagulation alone (n=199) and were followed for 6 months. Patients with a contraindication to anticoagulation therapy and those with recurrence despite adequate anticoagulation were excluded. Results were published in the April 28 Journal of the American Medical Association. 

Filters were successfully inserted in 193 patients, and they were retrieved, at 3 months after placement, in 153 of the 164 patients in whom retrieval was attempted. By 3 months, 6 patients in the filter group had a recurrent PE (3.0% of the group, all were fatal), compared to 3 patients in the anticoagulation-only group (1.5% of the group; 2 fatal; P=0.50 for PE recurrence). The groups also had similar rates of recurrence within 6 months, symptomatic deep venous thrombosis, major bleeding, and mortality within 3 or 6 months. Filter thrombosis occurred in 3 patients. One patient died of cardiac arrest during filter insertion.

Implantation of the filters did not reduce risk of symptomatic PE recurrence, and thus the study's results do not support use of inferior vena cava filters in PE patients who can be treated with anticoagulation, the study authors concluded. The rate of PE recurrence in the study was less than expected, but this shows that "modern management with full-dose anticoagulation is likely very effective even in patients usually considered to be at high risk for recurrence," the authors wrote.

The study was limited by its open-label design and its small size, and the results do not exclude the possibility of benefit from filters in certain subgroups of patients with venous thromboembolism, such as those with PE and hemodynamic instability. The study used the ALN brand of filter (provided by the manufacturer for the study), but given existing evidence of similarities among retrievable filter models, the results are probably applicable to other retrievable filters, the authors said.

Fecal transplants for recurrent C. diff may resolve symptoms with few adverse events

Low-strength evidence shows fecal microbiota transplantation (FMT) effectively treats recurrent Clostridium difficile infections (CDIs), with few short-term adverse events, a review found.

annals.jpg

Researchers conducted a literature search to find 2 randomized, controlled trials (RCTs); 28 case-series studies; and 5 case reports (included only for reporting harms) assessing FMT. Results of their analysis, which was funded by the Department of Veterans Affairs, appeared in the May 5 Annals of Internal Medicine. 

Across all studies of FMT for recurrent CDI, symptom resolution was seen in 85% of cases. In the 2 RCTs, totaling 36 patients with recurrent CDI, 27 (75%) had resolution of CDI symptoms without recurrence. One RCT comparing FMT with 2 control groups reported resolution of symptoms in 81% of patients who received FMT, 31% of patients who received vancomycin, and 23% of patients who received vancomycin plus bowel lavage (P<0.001 for both control groups vs. FMT). An RCT comparing different FMT routes of administration for CDI recurrence reported no difference between groups (60% had their symptoms resolved in the nasogastric tube group, as did 80% in the colonoscopy group; P=0.63). Among the 480 patients in 21 case-series studies who received FMT for recurrent CDI, 85% had resolution of symptoms without recurrence.

There were 7 studies reporting on patients with refractory CDI treated with FMT, and they used various methods and did not compared FMT with standard therapy. Reported resolution of symptoms ranged widely (0% to 100%; overall resolution rate, 55%).

Case-series studies included 7 patients treated with FMT for initial CDI, with mixed results. Six cases were part of a series of 14 patients with refractory CDI, and 1 case was part of a series of 4 patients. Among the 6 cases, 1 was cured after FMT. The other, single case received FMT as initial treatment of an episode of postantibiotic-associated colitis and had symptom resolution within 48 hours.

"[L]ow-strength evidence supports FMT as having a substantial effect and few short-term adverse events for adults with recurrent CDI," the authors wrote. "There is insufficient evidence about FMT for patients with refractory CDI or for initial treatment of CDI. Evidence is insufficient about whether treatment effects vary by FMT donor, preparation, or delivery method."

The author of an accompanying editorial stated that FMT is effective, provides durable cures, and can result in a cost savings of $17,000 per patient in recurrent cases. Remaining issues include the need for regulations to standardize the treatment, which is currently considered a biologic by the FDA, and the potential effects of transplanting a microbiome from one patient to another.

"The excitement about FMT is justified given its high efficacy in treating recurrent CDI, relative availability and simplicity, and favorable cost profile compared with other therapies," the editorial stated.

Wednesday, March 18, 2015

Restrictive vs. liberal transfusion strategies may not matter after cardiac surgery

Restrictive transfusion thresholds after cardiac surgery didn't improve outcomes compared to liberal ones, a study found.

The Transfusion Indication Threshold Reduction (TITRe2), a multicenter, parallel-group trial, recruited patients age 16 and older undergoing nonemergency cardiac surgery at 17 British centers. Patients with a postoperative hemoglobin level of less than 9 g/dL were randomly assigned to a restrictive transfusion threshold of hemoglobin level <7.5 g/dL (n=1,000) or a liberal transfusion threshold of <9 g/dL (n=1,003). In the liberal-threshold group, patients received 1 unit of red cells immediately after randomization and received another unit if the hemoglobin level remained or dropped below 9 g/dL again. In the restrictive-threshold group, patients received 1 unit if the hemoglobin level dropped below 7.5 g/dL and another unit if the level remained or dropped below 7.5 g/dL again.

The primary outcome was a composite of a serious infection (sepsis or a wound infection) or an ischemic event such as a permanent stroke, myocardial infarction, infarction of the gut, or acute kidney injury within 3 months. Health care costs, excluding the index surgery, were estimated from the day of surgery to 3 months afterward. Results appeared in the March 12 New England Journal of Medicine. 

Transfusion rates after randomization were 53.4% in the restrictive strategy group and 92.2% in the liberal strategy group. Primary outcomes occurred in 35.1% of the patients in the restrictive-threshold group and 33.0% of the patients in the liberal-threshold group (odds ratio, 1.11; 95% CI, 0.91 to 1.34; P=0.30). There were more deaths in the restrictive-threshold group than in the liberal-threshold group (4.2% vs. 2.6%; hazard ratio=1.64; 95% CI, 1.00 to 2.67; P=0.045). The researchers noted that serious postoperative complications, excluding primary-outcome events, occurred in 35.7% of participants in the restrictive-threshold group and 34.2% of participants in the liberal-threshold group. Total costs did not differ significantly between the groups.

The study creates new uncertainty about using a restrictive threshold for transfusion after cardiac surgery, the researchers wrote. The TITRe2 trial differs from previous observational studies of transfusion thresholds in that all the participants had cardiovascular disease and a substantial proportion of participants were likely to have been dependent on oxygen supplementation immediately after surgery. This group may have been at the limits of their cardiovascular reserve and may benefit from higher hemoglobin levels, the authors speculated. "Patients with cardiovascular disease may represent a specific high-risk group for which more liberal transfusion thresholds are to be recommended," they wrote.

The results are surprising, said an accompanying editorial. "Cardiac surgery departments should review the findings of the TITRe2 trial and decide which threshold they deem to be most appropriate for transfusion. Protocols should be developed to minimize deviation from the agreed-upon approach, and feedback should be provided to hold operators accountable to the institution's standard of care," the editorialist wrote.

Tuesday, February 3, 2015

Lighter Jogging May Be Better Than Strenuous Jogging.

TIME (2/3, Park) reports that research published in the Journal of the American College of Cardiology suggests that individuals “who push their bodies too hard may essentially undo the benefit of exercise.”

Bloomberg News (2/3, Ostrow) reports that investigators “looked at 5,048 people in the Copenhagen City Heart Study, a long-term examination of thousands of people that has been the basis for many reports on cardiovascular health.” The investigators “sifted 12 years’ worth of data on 1,098 healthy joggers and 413 healthy but sedentary non-joggers.” The investigators “found those who jogged one to 2.4 hours a week at a slow or average pace with no more than three running days in a week had the best survival rates.”

The Los Angeles Times (2/3, Morin) “Science Now” blog reports that “strenuous joggers – people who ran faster than 7 mph for more than four hours a week; or who ran faster than 7 mph for more than 2.5 hours a week with a frequency of more than three times a week – had a mortality rate that ‘is not statistically different from that of the sedentary group,’ the authors wrote.”


Thursday, December 11, 2014

Higher Insulin Doses May Increase Risks for Patients with Type 2 Diabetes

Researchers have uncovered a link between an increased dosage of insulin and a heightened risk of premature death and other events in patients with type 2 diabetes. The observational study included 6484 patients with type 2 diabetes who progressed to treatment with insulin monotherapy and were followed for an average of 3.3 years. Increased risks in relation to 1-unit increases in insulin dose were 54% for all-cause mortality, 37% for major adverse cardiovascular events, and 35% for cancer during follow-up. The results are published in Diabetes, Obesity, and Metabolism.


Wednesday, December 10, 2014

BPA Exposure from Canned Beverages May Increase Blood Pressure

In a new study, when older adults drank 2 cans of soy milk, their average concentration of urinary bisphenol A (BPA) increased 16 times above baseline within 2 hours. Systolic blood pressure increased 4.5 mm Hg on average. On days when they drank the same beverage from glass bottles, which do not use BPA linings, there was no significant change in their BPA levels or blood pressure. The Hypertension study included 60 older adults who drank soy milk from cans or glass bottles on 3 separate occasions, weeks apart. BPA is an endocrine disruptor that can mimic estrogen.

Report: Half Of Patients Prescribed Opioid For 30 Days Still Using Drug Three Years Later.

In continuing coverage, ABC World News (12/9, story 7, 1:10, Muir) Chief Medical Editor Dr. Richard Besser reported on a study from Express Scripts that looked at 36 million prescriptions and found that “nearly half of those patients who are described a narcotic and took it for more than 30 days, they were still on it three years later.” Dr. Besser said these drugs “are meant for short-term use,” and according to the CDC “46 people die from narcotic overdose, when they are combined with anxiety medication or sleeping pills” every day.

TIME (12/10, Sifferlin) reports that although “the rate of Americans using pain medications like codeine, morphine, oxycodone and hydrocodone long term has remained stable in the last five years,” the amount “of medication they take has increased.” The report found that “use was most rampant in small Southeastern cities, and two-thirds of patients were prescribed the drugs by two or more physicians.” Nearly “40% filled their prescriptions at multiple pharmacies.”

CBS News (12/10) reports on its website that according to the National Institute on Drug Abuse, “the U.S. accounts for only 5 percent of the world’s population, yet as a country we consume at least 75 percent of all opioid prescription drugs.”